Study Data from Castle Biosciences' Collaboration with the National Cancer Institute's SEER Program Registries Published in JCO Precision Oncology

Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes

Related Keywords

United States ,American ,Matthew Goldberg ,Derek Maetzold ,Castle Biosciences ,Linkedin ,Castle Biosciences Inc ,Program Registries ,American Joint Committee On Cancer Eighth Edition ,Nasdaq ,Twitter ,Facebook ,Securities Exchange ,Instagram ,American Joint Committee ,Cancer Eighth Edition ,Decisiondx Melanoma ,Mypath Melanoma ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Gene Expression Profile Testing ,Cutaneous Melanoma ,Survival Outcomes ,Population Based Analysis ,